Abstract:

BACKGROUND: CXC-chemokine ligand 16 (CXCL16) is an important chemokine involved in inflammatory reaction, and plays a key role in the occurrence of coronary atherosclerosis.
OBJECTIVE: To investigate the changes of serum CXCL16 in stable angina pectoris (SAP) patients who were implanted with rapamycin eluting stent.
METHODS: Forty SAP patients were selected from the Department of Cardiology, the First Affiliated Hospital of Zhengzhou University. They underwent implantation of one or two rapamycin eluting stents. Another 10 health persons confirmed by coronary angiography were selected as controls. Serum CXCL16 and high-sensitivity C-reactive protein (Hs-CRP) were studied in all the subjects.
RESULTS AND CONCLUSION: Compared with the control group, the serum CXCL16 showed higher levels in SAP patients prior to stent implantation and 0.5, 2, 24 hours after stent implantation (P < 0.05); the serum CXCL16 level increased at 0.5 and 2 hours after stent implantation compared with before stent implantation (P < 0.01). At 0.5, 2 and 24 hours after stent implantation, the levels of Hs-CRP in the SAP group were significantly higher than those in the control group (P < 0.01); no significant difference in Hs-CRP levels was found (P > 0.05), while the level of Hs-CRP at 2 hours was higher than that at 24 hours (P < 0.05). Serum CXCL16 is positively correlated with Hs-CRP (r=0.632,P=0.017).